Skip to main content

*67% of patients with commercial insurance have 1st line coverage.1

*As evidenced by ARR, MRI (Gd+ T1 and T2 lesions), and 3- and 6-month CDP.2 
Real patient who was compensated for time. Individual results may vary.

I’m glad I started RMS treatment with KESIMPTA

Real patient who was compensated for time. Individual results may vary.

Alongside KESIMPTA is here to support your patients
 80% of commercial patients receive their first bridge dose in 4 days2

Based on prescription data collected from April to September 2023.

your eligible, commercially insured patients pay as little as a $0† copay

Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state health insurance program. Patients with commercial insurance coverage for KESIMPTA may receive up to $18,000 in annual copay benefits. Patients with commercial insurance and an initial denial of coverage may receive up to 12 months of free product while coverage is pursued. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions at

ARR, annualized relapse rate; CDP, confirmed disability progression; DMT, disease-modifying therapy; Gd+, gadolinium-enhancing; MOA, mechanism of action; MRI, magnetic resonance imaging; MS, multiple sclerosis; RMS, relapsing multiple sclerosis; SC, subcutaneous.


Contraindications: KESIMPTA is contraindicated in patients with active hepatitis B virus (HBV) infection, or history of hypersensitivity to ofatumumab, or life-threatening injection-related reaction to KESIMPTA. Hypersensitivity reactions have included anaphylaxis and angioedema.

Warnings and Precautions

Infections: Serious, including life-threatening or fatal, bacterial, fungal, and new or reactivated viral infections have been observed during and following completion of treatment with anti-CD20 B-cell depleting therapies....


KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults...

CoverMyMeds is a registered trademark of CoverMyMeds, LLC.
References: 1. Data on file. Coverage Change-ESI. Novartis Pharmaceuticals Corp; East Hanover, NJ. May 2024. 2. Kesimpta. Prescribing information. Novartis Pharmaceuticals Corp. 3. Data on file. Injection time. Novartis Pharmaceuticals Corp; East Hanover, NJ. June 2020. 4. Data on file. Program data. Novartis Pharmaceuticals Corp; East Hanover, NJ. November 2023.